Skip to main content
Holly Kramer on Muck Rack

Holly Kramer

As seen in: Nature, Wiley Online Library, The Globe and Mail, The Hill, Medscape, Grand Rapids Press, MLive, Dove Medical Press, Healio, HCP Live and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Holly

Contact Holly, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Crisis Point: The Cause and Calamity, Neighborhood Disadvantage and Kidney Disease

|
By Mary Roberts, Adrian Brown, Salvatore G Viscomi, Vahakn B. Shahinian, Holly Kramer, Maya Clark Cutaia
| consultantlive.com
The Landscape: 24 Million Left Behind Data from the US Census Bureau identify 24 million Americans living in disadvantaged neighborhoods, defined as communities where at least 1 in 5 residents falls below the federal poverty line.1 The inequities embedded within these communities create profound barriers to healthcare access, barriers that are especially consequential for silent diseases like chronic kidney disease (CKD), where delayed diagnosis and limited resources can mean irreversible...
Open in Who Shared View Duplicates (2) Issue with article?

1 Year After CKD Approval, Semaglutide Transforms Diabetes, Kidney, and Heart Care

|
By Diana Isaacs, Janani Rangaswami, Holly Kramer, Vlado Perkovic
| consultantlive.com
Just 1 year ago, semaglutide (Ozempic) was approved by the US Food and Drug Administration (FDA) for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This approval marked an important milestone as the first GLP-1 receptor agonist to reduce the risk of worsening kidney disease, kidney failure, and death due to cardiovascular disease in these patient populations. What is a GLP-1?
Open in Who Shared View Duplicates (2) Issue with article?

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

|
By Holly Kramer, George Bakris
| Wiley Online Library Verified
Introduction Cardiovascular disease (CVD) affects almost 30 million United States (US) adults and accounted for over 900,000 deaths in 2020 [1]. Interventions, such as blood pressure control, reductions in smoking prevalence, and use of cholesterol-lowering medications, have successfully lowered CVD mortality rates over the past 60 years [2]. However, CVD burden is trending upward [3].
Open in Who Shared Issue with article?
See all 20 licensed articles (38 Total)